Skip NavigationSkip to Content
Return Return to Search Results

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

  1. Author:
    Myers, R. M.
    Greiner, S. M.
    Harvey, M. E.
    Griesmann, G.
    Jkuffel, M.
    Buhrow, S. A.
    Reid, J. M.
    Federspiel, M.
    Ames, M. M.
    Dingli, D.
    Schweikart, K.
    Welch, A.
    Dispenzieri, A.
    Peng, K. W.
    Russell, S. J.

  2. Author Address

    Mayo Clin, Dept Mol Med, Rochester, MN 55905 USA. Mayo Clin, Toxicol Core, Rochester, MN USA. Mayo Clin, Viral Vector Prod Lab, Rochester, MN USA. Mayo Clin, Dept Pharmacol & Expt Therapeut, Rochester, MN USA. Mayo Clin, Div Hematol, Rochester, MN USA. NCI, Dev Therapeut Program, Toxicol & Pharmacol Branch, Bethesda, MD 20892 USA. NCI, Dev Therapeut Program, Biol Resources Branch, Frederick, MD 21701 USA.;Russell, SJ, Mayo Clin, Dept Mol Med, Rochester, MN 55905 USA.;sjr@mayo.edu
    1. Year: 2007
    2. Date: Dec
  2. Journal: Clinical Pharmacology & Therapeutics
    1. 82
    2. 6
    3. Pages: 700-710
  4. Type of Article: Article
  5. ISSN: 0009-9236
  1. Abstract:

    MV-NIS is an oncolytic measles virus encoding the human thyroidal sodium iodide symporter (NIS). Here, we report the results of preclinical pharmacology and toxicology studies conducted in support of our clinical protocol "Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma.'' Dose-response studies in the KAS-6/1 myeloma xenograft model demonstrated a minimum effective dose of 4 x 10(6) TCID50 (tissue culture infectious dose 50)/kg. Toxicity studies in measles-naive squirrel monkeys and measles-susceptible transgenic mice were negative at intravenous doses up to 10(8) and 4 x 10(8) TCID50/kg, respectively. Abundant viral mRNA, maximal on day 8, was detected in cheek swabs of squirrel monkeys, more so after pretreatment with cyclophosphamide. On the basis of these data, the safe starting dose of MV-NIS for our clinical protocol was set at 1-2 x 10(4) TCID50/kg (10(6) TCID50 per patient).

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1038/sj.clpt.6100409
  3. View record in Web of Science®
  4. WOS: 000251086400019

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel